U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H29NO
Molecular Weight 311.4611
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of UR-144

SMILES

CCCCCN1C=C(C(=O)C2C(C)(C)C2(C)C)C3=CC=CC=C13

InChI

InChIKey=NBMMIBNZVQFQEO-UHFFFAOYSA-N
InChI=1S/C21H29NO/c1-6-7-10-13-22-14-16(15-11-8-9-12-17(15)22)18(23)19-20(2,3)21(19,4)5/h8-9,11-12,14,19H,6-7,10,13H2,1-5H3

HIDE SMILES / InChI

Molecular Formula C21H29NO
Molecular Weight 311.4611
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.who.int/medicines/areas/quality_safety/4_8_Review.pdf

UR-144 is a potent synthetic cannabinoid designed by Abbott Laboratories as a CB2 selective agonist for pain management and other indications. UR-144 preferentially binds the peripheral CB2 receptor (Ki = 1.8 nM) over the central CB1 receptor (Ki = 150 nM). Pre-clinical studies of nociceptive and neuropathic pain have shown that CB2-selective ligands are analgesics without causing the adverse side effects linked with CB1 receptor activation. However, UR-144 has no therapeutic application. According to the FDA (US Food and Drug Administration) there are currently no approved or on-going drug applications for the medical use of UR-144.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Patents

Patents

Sample Use Guides

UR-144 (10 and 30 mg/kg) depressed the locomotor activity in mice in a time and dose-dependent manner and with an ID50-value of 7.8 mg/kg
Route of Administration: Unknown
UR-144 preferentially binds the peripheral CB2 receptor with Ki = 1.8 nM.
Substance Class Chemical
Created
by admin
on Sat Dec 16 10:25:25 UTC 2023
Edited
by admin
on Sat Dec 16 10:25:25 UTC 2023
Record UNII
1TYA7HVP1B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
UR-144
Code English
2,2,3,3-TETRAMETHYLCYCLOPROPYL(1-PENTYL-1H-INDOLE-3-YL) KETONE
Systematic Name English
(1-PENTYL-1H-INDOL-3-YL)(2,2,3,3-TETRAMETHYLCYCLOPROPYL)METHANONE
Systematic Name English
J3.184.806G
Code English
TMCP-018
Code English
YX-17
Code English
KM-X1
Code English
DEA NO. 7144
Code English
METHANONE, (1-PENTYL-1H-INDOL-3-YL)(2,2,3,3-TETRAMETHYLCYCLOPROPYL)-
Systematic Name English
Classification Tree Code System Code
DEA NO. 7144
Created by admin on Sat Dec 16 10:25:25 UTC 2023 , Edited by admin on Sat Dec 16 10:25:25 UTC 2023
WIKIPEDIA Designer-drugs-UR-144
Created by admin on Sat Dec 16 10:25:25 UTC 2023 , Edited by admin on Sat Dec 16 10:25:25 UTC 2023
Code System Code Type Description
CAS
1199943-44-6
Created by admin on Sat Dec 16 10:25:25 UTC 2023 , Edited by admin on Sat Dec 16 10:25:25 UTC 2023
PRIMARY
WIKIPEDIA
UR-144
Created by admin on Sat Dec 16 10:25:25 UTC 2023 , Edited by admin on Sat Dec 16 10:25:25 UTC 2023
PRIMARY
FDA UNII
1TYA7HVP1B
Created by admin on Sat Dec 16 10:25:25 UTC 2023 , Edited by admin on Sat Dec 16 10:25:25 UTC 2023
PRIMARY
PUBCHEM
44626619
Created by admin on Sat Dec 16 10:25:25 UTC 2023 , Edited by admin on Sat Dec 16 10:25:25 UTC 2023
PRIMARY
EPA CompTox
DTXSID60152635
Created by admin on Sat Dec 16 10:25:25 UTC 2023 , Edited by admin on Sat Dec 16 10:25:25 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> AGONIST
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
TARGET -> AGONIST
Mouse AtT-20 neuroblastoma cells stably transfected with human CB2
EC50
Related Record Type Details
METABOLITE ACTIVE -> PARENT
Agonist of Human cannabinoid 1 & 2 receptors (CB1, CB2); Ki=680 nM (CB1), 0.71 nM(CB2)
IN-VITRO
Scientific Literature
METABOLITE -> PARENT
10 ng/mL (urine, ER arrival), 58 ng/mL (serum, ER arrival), 32 ng/mL (serum, 10h after ER arrival)
IN-VIVO
URINE
METABOLITE -> PARENT
22 ng/mL (serum, ER arrival); 10 ng/mL (serum, 10h after ER arrival)
IN-VIVO
Scientific Literature
Related Record Type Details
ACTIVE MOIETY
Human cannabinoid 1 receptor (CB1) and 2 receptor (CB2) agonist; Ki=150 nM (CB1), 1.8 nM (CB2)
IN-VITRO
Ki